R Vora - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

R Vora

Showing results (61-70 of 63) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 63 results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerE R Brown, K A Charles, S A Hoare, et al.

Cancer Cell|July 9, 2014

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.

Nature Communications|February 13, 2016

A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiologyEric A Hungate, Sapana R Vora, Eric R Gamazon, et al.

Pageof 7

Search research articles

Showing results (61-70 of 63) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 63 results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerE R Brown, K A Charles, S A Hoare, et al.

Cancer Cell|July 9, 2014

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.

Nature Communications|February 13, 2016

A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiologyEric A Hungate, Sapana R Vora, Eric R Gamazon, et al.

Pageof 7